Overview
Autolomous develops critical manufacturing management systems and digital platforms for cell and gene therapy (CGT) production. Their AutoloMATE solution streamlines data management and automates workflows to help manufacturers reduce costs, scale operations, and deliver therapies to more patients. The company partners with CDMOs and advanced therapy manufacturers to implement digitized supply chain ecosystems and gain operational efficiencies.
Frequently asked questions
- What specific solutions does Autolomous offer for CGT manufacturing?
- Autolomous provides AutoloMATE, a fully integrated data management platform designed specifically for advanced therapy manufacturing. The platform enables manufacturers to streamline workflows, automate processes, and gain new insights through digitized supply chain ecosystems.
- Who are Autolomous's typical customers?
- Autolomous serves cell and gene therapy manufacturers, including contract development and manufacturing organizations (CDMOs). The company has demonstrated partnerships with organizations like the Center for Breakthrough Medicines and collaborates with industry bodies such as the Cell and Gene Therapy Catapult.
- How does Autolomous help reduce manufacturing costs?
- By providing critical manufacturing management systems that automate and streamline CGT production workflows, Autolomous enables manufacturers to reduce operational costs and scale their operations more efficiently, ultimately allowing them to deliver therapies to more patients.